News

Public · Published

Key facts: FDA wins; Ultragenyx exits studies, targets 2027 profit

Ultragenyx said it will end GTX-102 studies for Angelman syndrome and stop UX701 for Wilson disease after it failed to advance to Phase 3. It will redirect research spending, cut about 20% of its workforce, reaffirm its 2027 profit target, and reported FDA approvals for two medicines.

Published:

Updated:

What happened

Ultragenyx said it will end GTX-102 studies for Angelman syndrome and stop UX701 for Wilson disease after it failed to advance to Phase 3. It will redirect research spending, cut about 20% of its workforce, reaffirm its 2027 profit target, and reported FDA approvals for two medicines.

Confirmed

Global impact / market context

Ending studies and reducing staff can lower research and administrative costs, supporting the company’s 2027 profitability goal, but also narrows its active development work. The two FDA approvals and progressing launches could provide sales opportunities, though the article gives no revenue forecasts or launch results.

Analyst inference

The article reports an average 12-month analyst price target of $26.40, up from $26.25, and says it implies 59% upside from the Nov. 3 close. Ratings are split between 11 Buy and 11 Hold, with no Sell ratings; these are analyst views, not outcomes.

Confirmed

What to watch

  1. Watch for details on the two approved medicines’ launch progress and sales, because commercial uptake would show whether new products can contribute revenue as research priorities shift. Analyst inference
  2. Check whether Ultragenyx provides updated cost savings or a revised 2027 profitability outlook after the workforce reduction and lower projected research and administrative costs. Analyst inference
  3. The company expects restructuring charges in late 2026; their disclosed size and timing would clarify how the workforce reduction affects costs before the 2027 target. Confirmed

Evidence

  • Original source link unavailable